New hope for Hard-to-Treat breast cancer: Real-World study launches
Disease control
Recruiting now
This study follows about 300 women with HER2-positive breast cancer that has spread. They are getting a three-drug combination (tucatinib, capecitabine, trastuzumab) as part of their normal care. The goal is to see how well the treatment works and how safe it is in everyday medic…
Sponsor: Fondazione Oncotech • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC